ABPI response to NICE 5 year strategy

NICE has launched its 5-year strategy which it says will help to speed up patients’ access to the latest and most effective treatments.

Pharmaceutical companies are working on thousands of exciting new medicines and treatments, from rare disease gene therapies to mRNA vaccines for cancer. Richard Torbett

In response, Richard Torbett, Chief Executive of the ABPI, said:

“Pharmaceutical companies are working on thousands of exciting new medicines and treatments, from rare disease gene therapies to mRNA vaccines for cancer. Today’s strategy sets out a positive vision for the future of NICE; one which will see it evolve with the science that makes these breakthroughs possible and build on its international reputation for producing evidence-based guidance.

“We will continue to work with NICE to ensure medicine appraisals remain robust, transparent, and in line with the latest science so that NHS patients can benefit from new medicines when they become available.”

TAGS
  • NICE

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.